专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪75.43万元。 分行业来看，化学制品行业董秘薪酬总额1.24亿元，平均年薪70.7万元。 注：数据来源于choice，截止2024年末任期不满1年的不参与统计。计算薪酬同比变动幅度时，截止 2023年末任期不满1年的不参与统计。 按年龄来看，化学制品行业董秘年龄普遍超过（含）40岁，最年轻董秘为圣达生物实控人洪爱之女朱怡 萱，1999年生，硕士学历，2023年3月起任公司董秘，彼时年仅24岁。 2024年，朱怡萱薪酬66.1万元，与上年持平，略低于行业平均薪酬，但高于同行业55%以上的董秘。公 司经营业绩层面，圣达生物2024年营收为8.27亿元，同比增长13.75%，净利润为0.29亿元，同比增长 154.43%。 按职务重合来看，存在董秘兼任CFO情形的上市公司占比17.14%。 按任职时长来看，百川股份陈慧敏自2006年12月起任公司董秘， ...

Core Viewpoint - The company, Shengda Biology, announced the use of idle raised funds for cash management, indicating a strategic move to enhance liquidity and yield on its financial resources [1] Group 1: Financial Management - Shengda Biology and its subsidiaries will utilize up to RMB 23,000.00 million of temporarily idle raised funds for cash management [1] - The total amount for this cash management initiative is RMB 5,000.00 million, which will be invested in structured deposit products from the Bank of China [1] - The expected annualized yield for the investment ranges from 0.60% to 1.80%, with a product duration of 32 days [1]

证券代码：603079 证券简称：圣达生物 公告编号：2025-040 浙江圣达生物药业股份有限公司 关于使用闲置募集资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资种类：中国银行公司客户结构性存款产品 投资额度：5,000.00万元 （一）投资目的 为提高募集资金使用效率，合理利用暂时闲置募集资金，在确保不影响募集 资金投资项目建设和使用、募集资金安全的情况下，增加公司的收益，为公司及 股东获取更多回报。 已履行的审议程序：浙江圣达生物药业股份有限公司（以下简称"公 司"）于2025年7月7日召开第四届董事会第十八次会议和第四届监事会第十六次 会议，审议通过了《关于使用闲置募集资金进行现金管理的议案》，同意公司及 子公司使用额度不超过人民币23,000.00万元的暂时闲置募集资金进行现金管理， 用于购买安全性高、流动性好、有保本约定、产品期限不超过12个月的银行等金 融机构现金管理产品（包括但不限于结构性存款、大额存单等）。在上述期限及 额度内，资金可滚动使用，并授权公司董事长 ...

Core Viewpoint - The stock price of Shengda Bio as of August 5, 2025, is 18.35 yuan, reflecting a decrease of 0.49% from the previous trading day, with a trading volume of 0.77 billion yuan and a turnover rate of 2.44% [1] Company Overview - Shengda Bio specializes in the research, production, and sales of biotin, folic acid, and other vitamin products, which are widely used in feed, food, and pharmaceutical industries [1] - The company operates in sectors including chemical products, synthetic biology, and vitamins [1] Financial Performance - Shengda Bio expects a net profit attributable to shareholders of the listed company for the first half of 2025 to be between 35 million yuan and 45 million yuan, representing a year-on-year growth of 112.19% to 172.81% [1] Capital Flow - On August 5, 2025, the net outflow of main funds was 16.8795 million yuan, with a cumulative net outflow of 37.7823 million yuan over the past five days [1]

Group 1 - The legal opinion letter is issued by Zhejiang Tiance Law Firm regarding Zhejiang Shengda Biological Pharmaceutical Co., Ltd. for the purpose of the company's 2025 second extraordinary general meeting of shareholders [2][3]. - The law firm confirms that the meeting was convened and held in accordance with relevant laws, regulations, and the company's articles of association [3][4]. - The meeting utilized a combination of on-site and online voting methods, with specific voting times outlined [3][4]. Group 2 - The record date for the shareholders' meeting was set for July 18, 2025 [4]. - A total of 4 shareholders attended the meeting in person, representing 90,225,545 shares, which accounted for a significant portion of the voting rights [5]. - An additional 155 shareholders participated via online voting, representing 1,979,176 shares [5]. Group 3 - The voting results showed that 92,128,565 shares were in favor of the proposals, 48,156 shares were against, and 28,000 shares abstained, resulting in a passing rate of 99.9174% [6]. - All resolutions passed were special resolutions, requiring more than two-thirds of the valid voting rights to be approved [6]. - The law firm concluded that the meeting's procedures and voting results were legal and valid [6].

浙江天册律师事务所 关于 浙江圣达生物药业股份有限公司 2025 年第二次临时股东大会的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼邮编 310007 电话：0571 8790 111 传真：0571 8790 1500 https://www.tclawfirm.com/ 法律意见书 浙江天册律师事务所 关于浙江圣达生物药业股份有限公司 2025 年第二次临时股东大会的 法律意见书 编号：TCYJS2025H1218 号 一、本次股东大会召集、召开的程序 （一）经本所律师核查，公司本次股东大会由董事会提议并召集，召开本次股 东大会的通知已于 2025 年 7 月 8 日在指定媒体及上海证券交易所网站上公告。 （二）本次股东大会采取现场投票与网络投票相结合的方式。 法律意见书 根据本次股东大会的会议通知，本次股东大会现场会议召开的时间为 2025 年 7 月 23 日 13 点 30 分；召开地点为浙江省天台县福溪街道始丰东路 18 号，公司会 议室。经本所律师的审查，本次股东大会现场会议召开的实际时间、地点与本次股 东大会的会议通知中所告知的时间、地点一致。 致：浙江圣达生物药业股 ...

证券代码：603079 证券简称：圣达生物 公告编号：2025-039 浙江圣达生物药业股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 7 月 23 日 (二)股东大会召开的地点：浙江省天台县福溪街道始丰东路 18 号,公司会议室 1、 议案名称：《关于修改<公司章程>并办理工商变更登记的议案》 审议结果：通过 表决情况： | 股东类型 | 同意 | | 反对 | | 弃权 | | | --- | --- | --- | --- | --- | --- | --- | | | 票数 | 比例（%） | 票数 | 比例 | 票数 | 比例 | | | | | | （%） | | （%） | | A 股 | 92,128,565 | 99.9174 | 48,156 | 0.0522 | 28,000 | 0.0304 | (三)出席会议的普通股股东和恢复表决权的优先股股 ...

Core Points - The company, Zhejiang Shengda Biological Pharmaceutical Co., Ltd., is holding its second extraordinary general meeting of shareholders on July 23, 2025, to discuss important matters including amendments to the Articles of Association [1][2][4]. Meeting Details - The meeting will take place at the company's conference room located at 18 Shifeng East Road, Fuxi Street, Tiantai County, Zhejiang Province, starting at 13:30 [1]. - Shareholders can participate through both on-site attendance and online voting via the Shanghai Stock Exchange's voting system during specified time slots on the same day [2][4]. Agenda Items - The primary agenda item is to amend the Articles of Association and handle the necessary business registration changes [1][5]. - The company has completed the issuance of 17,840,666 shares, increasing the total number of shares from 171,188,958 to 189,029,624, which raises the registered capital from 171,188,958 RMB to 189,029,624 RMB [4][5]. Changes to Company Structure - The name of one of the company's founders, Zhejiang Hongbo Enterprise Management Co., Ltd., will be changed to Ningbo Xuande Investment Co., Ltd. [5]. - Specific clauses in the Articles of Association will be revised to reflect the changes in total shares and registered capital, while other contents will remain unchanged [5][6]. Legal and Procedural Aspects - The meeting will be conducted in accordance with the company's Articles of Association and relevant laws, ensuring the protection of shareholders' rights and orderly proceedings [2][4]. - A legal representative from Zhejiang Tiance Law Firm will be present to witness the meeting and provide a legal opinion [4].

证券代码：603079 浙江圣达生物药业股份有限公司 2025 年第二次临时股东大会会议材料 二〇二五年七月 浙江圣达生物药业股份有限公司 2025 年第二次临时股东大会会议材料 | 目录 | | --- | | 2025 | 年第二次临时股东大会会议议程 | | 1 | | --- | --- | --- | --- | | 2025 | 年第二次临时股东大会会议须知 | | 3 | | 议案一：关于修改《公司章程》并办理工商变更登记的议案 | | 5 | | 浙江圣达生物药业股份有限公司 2025 年第二次临时股东大会会议材料 浙江圣达生物药业股份有限公司 2025 年第二次临时股东大会会议议程 一、会议时间 现场会议：2025 年 7 月 23 日(星期三)下午 13:30 网络投票：2025 年 7 月 23 日(星期三)采用上海证券交易所网络 投票系统，通过交易系统投票平台的投票时间为股东大会召开当日的 交 易 时 间 段 ， 即 2025 年 7 月 23 日 9:15-9:25 ， 9:30-11:30 ， 13:00-15:00；通过互联网投票平台的投票时间为股东大会召开当日 的 9:15-1 ...

[Current Period Performance Forecast](index=1&type=section&id=I.%20Current%20Period%20Performance%20Forecast) The company anticipates substantial growth in its 2025 semi-annual performance, with significant increases in both net profit and non-recurring net profit attributable to shareholders 2025 Semi-Annual Performance Forecast vs. Prior Period | Indicator | 2025 Semi-Annual Forecast | 2024 Semi-Annual (Prior Period) | Year-on-Year Growth | | :--- | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders** | RMB 35 million - RMB 45 million | RMB 16.4948 million | 112.19% - 172.81% | | **Net Profit Attributable to Shareholders After Non-Recurring Items** | RMB 32 million - RMB 42 million | RMB 5.1514 million | 521.19% - 715.31% | - This performance forecast applies to situations where profitability is achieved, and net profit increases by **over 50%** compared to the same period last year[3](index=3&type=chunk) - The performance forecast period is from January 1, 2025, to June 30, 2025[4](index=4&type=chunk) - The company explicitly states that this performance forecast data has not been audited by a certified public accountant[5](index=5&type=chunk) [Prior Period Performance Overview](index=2&type=section&id=II.%20Prior%20Period%20Performance%20Overview) Key financial data for the first half of 2024 is provided as a benchmark, including net profit and non-recurring net profit attributable to the parent company 2024 Semi-Annual Key Financial Data | Indicator | 2024 Semi-Annual Data | | :--- | :--- | | **Total Profit** | RMB 24.1930 million | | **Net Profit Attributable to Shareholders** | RMB 16.4948 million | | **Net Profit Attributable to Shareholders After Non-Recurring Items** | RMB 5.1514 million | | **Earnings Per Share** | RMB 0.1/share | [Main Reasons for Performance Pre-Increase](index=2&type=section&id=III.%20Main%20Reasons%20for%20Current%20Period%20Performance%20Pre-Increase) Performance growth is primarily driven by optimized internal management, enhanced operational efficiency, and successful market expansion strategies - Internal Management Improvement: Continuous advancement of refined management and technological upgrades has enhanced operational efficiency and optimized costs[7](index=7&type=chunk) - Successful Market Strategy: Deepening differentiated competitive strategies and increasing market expansion efforts for bio-preservatives and functional ingredients have driven growth in this business segment[7](index=7&type=chunk) [Risk Warning and Other Disclosures](index=2&type=section&id=IV.%20Risk%20Warning) The company confirms no significant uncertainties affecting the forecast, reminding investors that preliminary data is subject to the final audited semi-annual report - The company confirms there are no other uncertain factors that could significantly impact the content of this performance forecast[8](index=8&type=chunk) - The company reminds investors that the forecast data is a preliminary calculation by the finance department and has not been audited; the final accurate data will be based on the company's officially disclosed 2025 semi-annual report, and investment risks should be noted[9](index=9&type=chunk)